학술논문
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
Document Type
article
Author
Daichi Fujimoto; Satoru Miura; Keisuke Tomii; Hiromitsu Sumikawa; Kenichi Yoshimura; Kazushige Wakuda; Yuko Oya; Toshihide Yokoyama; Takashi Kijima; Tetsuhiko Asao; Motohiro Tamiya; Atsushi Nakamura; Hiroshige Yoshioka; Takaaki Tokito; Shuji Murakami; Akihiro Tamiya; Hiroshi Yokouchi; Satoshi Watanabe; Ou Yamaguchi; Ryotaro Morinaga; Takayuki Jodai; Kentaro Ito; Yoshimasa Shiraishi; Yoshihito Kogure; Ryota Shibaki; Nobuyuki Yamamoto
Source
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Subject
Language
English
ISSN
2045-2322
Abstract
Abstract Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with pneumonitis. A multicenter, retrospective cohort study of patients with non-squamous non-small cell lung cancer who received a combination of platinum, pemetrexed, and pembrolizumab was conducted. Patients with confirmed pneumonitis established by an independent multidisciplinary team were enrolled. For 53 patients with pneumonitis, radiographic features at diagnosis predominantly comprised an organizing pneumonia pattern (62%, 33/53). Twelve (23%) patients experienced a worsening respiratory status during pneumonitis management, which was associated with a high mortality rate (58%, 7/12) during treatment. Severe grade at pneumonitis diagnosis (p